In addition to the two coronavirus vaccines that have already been registered by the Russian Federation, another twenty-four COVID-19 vaccine candidates were reported by Interfax to be in various stages of development.
Inna Kulikova, the director of the Russian Health Ministry's Department of Emergency Medical Care and Health Risk Management, stated at the Medicine and Quality 2020 conference held on December 8, 2020, "The Health Ministry of the Russian Federation registered the Gam-Covid-Vac (Sputnik V) vaccine on August 11, 2020, and the EpiVacCorona vaccine two months later.” 

In addition to the two coronavirus vaccines that have already been registered by the Russian Federation, another twenty-four COVID-19 vaccine candidates were reported by Interfax to be in various stages of development.
Inna Kulikova, the director of the Russian Health Ministry's Department of Emergency Medical Care and Health Risk Management, stated at the Medicine and Quality 2020 conference held on December 8, 2020, "The Health Ministry of the Russian Federation registered the Gam-Covid-Vac (Sputnik V) vaccine on August 11, 2020, and the EpiVacCorona vaccine two months later.” 

A clinical-stage biopharmaceutical company announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801. 
Altimmune, Inc. stated in a press release that ‘ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the USA.’

A Bermuda based clinical-stage company announced positive efficacy data from testing AM-301 nasal spray in vitro against a SARS-COV-2 coronavirus infection.
This study by Auris Medical Holding Ltd. reported up to 99.4 percent reduction of viral titer in human epithelial cell culture.

The Lancet published peer-reviewed, interim results of the Oxford COVID-19 vaccine (AZD1222) studies find that the vaccine protects against symptomatic disease in 70 percent of cases, with vaccine efficacy (VE) of 62 percent for those given 2 full doses.
Additionally, The Lancet disclosed on December 8, 2020, the VE was reported at 90 percent in those participants given a half, then a full dose (both trial arms pre-specified in the pooled analysis).

A systematic review and meta-analysis presented at the European Scientific Working Group on Influenza virtual conference on December 7, 2020, confirmed the benefit of an MF59®-adjuvanted trivalent seasonal influenza vaccine (aTIV) for adults 65 years and older.
As announced by Seqirus, the results indicate that relative vaccine effectiveness (rVE) favored aTIV over non-adjuvanted standard dose quadrivalent and trivalent influenza vaccines in averting influenza-related medical encounters. 

A new study found treating a SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours.
Researchers in the Institute for Biomedical Sciences at Georgia State University, led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.

Multiple research studies have shown that Black and Hispanic patients are more likely to receive a positive test result for COVID-19. However, a team of investigators at NYU Langone Health has found that once hospitalized, black patients were less likely to have a severe illness, die, or be discharged to hospice compared with white patients.

Researchers from the United Kingdom announced they used plants to produce virus-like particles (VLPs) of the dengue virus in a potential first step towards novel vaccines against the growing threat.
Led by Professor George Lomonossoff at the John Innes Centre in collaboration with Leaf Expression Systems published a pre-clinical study on October 25, 2020, which produced VLPs of dengue virus serotype 1, which is one of 4 serotypes of the virus.

A leading research institution located in Leuven, Belgium and Batavia Biosciences announced their partnership on the development of a vector-based COVID-19 vaccine candidate.
The virology team at the KU Leuven Rega Institute for Medical Research, which was founded in 1954, is headed by Prof. Dr. Johan Neyts, stated in a press release they ‘have developed a SARS-CoV-2 vaccine candidate consisting of an attenuated vector carrying the SARS-CoV-2 spike immunogen.’